WZX
The cell line is not validated yet.
HMSCATi009-A
General
Cell Line |
|
| hPSCreg name | HMSCATi009-A |
| Cite as: | HMSCATi009-A |
| Alternative name(s) |
WZX
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
ZJSHi001-A (ZJSHi-KCNB1) Donor's gene variants: KCNB1 Donor diseases: developmental and epileptic encephalopathy, 26 PFIZi023-A (B217c8) Donor's gene variants: GPR56, GPR56 Donor diseases: Bilateral Frontoparietal Polymicrogyria PUFHi004-A (TMEM163 c.227T>C p.(Leu76Pro) iPSC) Donor's gene variants: TMEM 163 Donor diseases: Leukodystrophy CBIGi007-A (IPSC0008, TMEM175 Q65P heterozygous) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi009-A (IPSC0012, TMEM175 M393T homozygous) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi010-A (SOD1 A4S, IPSC0014) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis CBIGi011-A (SOD1 I114T, IPSC0015) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis CBIGi013-A (IPSC0017, LRRK2 M1646T (heterozygous)) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi014-A (VAPB A2V, IPSC0019) Donor's gene variants: VAPB, VAPB Donor diseases: Amyotrophic Lateral Sclerosis CBIGi015-A (IPSC0020, LRRK2 N551K-R1398H-K1423K (protective haplotype)) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi016-A (IPSC0021, Parkin homozygous deletion between exon 3 and 4) Donor's gene variants: PRKN, PRKN Donor diseases: Parkinson Disease CBIGi022-A (IPSC0028, SOD1 I114T (CBIGi022-A)) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis |
| Last update | 19th December 2025 |
| User feedback | |
Provider |
|
| Generator | Stem Cell Application and Translation Laboratory (HMSCAT) |
| Owner | Stem Cell Application and Translation Laboratory (HMSCAT) |
External Databases |
|
| BioSamples | SAMEA117844298 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA117844300 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | No |
| a non-profit company? | No |
| a for-profit corporation? | No |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Medical Ethics Committee of Hebei Medical University |
| Approval number | 2021071 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
Yes |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| Medium |
Other medium:
Base medium: ncTarget hPSC medium
Main protein source: Knock-out serum replacement Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Unknown |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| TRA 1-81 |
Yes |
Morphology pictures
iPSCs
Differentiation Potency
In vitro directed differentiation
Morphology
Nestin
PAX6
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XX
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.